Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424

Phase II Study of a Temozolomide-Based Chemo-radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-term Results of Radiation Therapy Oncology Group (RTOG) 0424:



Publication date: Available online 3 April 2020

Source: International Journal of Radiation Oncology*Biology*Physics

Author(s): Barbara J. Fisher, Stephanie L. Pugh, David R. Macdonald, Arnab Chakravatri, Glenn J. Lesser, Sherry Fox, C. Leland Rogers, Maria Werner-Wasik, Thomas Doyle, Jean-Paul Bahary, John B. Fiveash, Joseph A. Bovi, Steven P. Howard, Hsiang-Hsuan Michael Yu, David D'Souza, Nadia N. Laack, Igor J. Barani, Young Kwok, Daniel R. Wahl, Jon F. Strasser